Survival curve analysis showed that the 5-year RFS rate was significantly lower in patients with PBRM1 loss than in those with PBRM1 retained in cancer cells (71.1% versus 96.1%, p < 0.001; Figure 6B). This evidence concerns the gene PBRM1 and cancer.